CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its
Dolaflexin® and other proprietary platforms, today announced that management will present a company overview at the
Credit Suisse 27th Annual Healthcare Conference in Scottsdale, Arizona on November 14, 2018 at 8:00 a.m. MST.
A live webcast of the presentation will be available on the Investors & Media section of Mersana’s website at
www.mersana.com. Archived replays will be available for approximately 60 days following the
presentation.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC
platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical
benefit to patients. Mersana’s product candidate XMT-1522 is in Phase 1 clinical trials in patients with advanced tumors
expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The Company’s second
product candidate, XMT-1536, is in Phase 1 clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer,
NSCLC and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.
Media Contact
Paul Kidwell
paulkidwell@mersana.com
617-680-1088
Investor Contact
Stern Investor Relations, Inc.
Christina Tartaglia
christina@sternir.com
212-362-1200